MOGAT3

Across TCGA pan-cancer cohorts, MOGAT3 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of MOGAT3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MOGAT3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MOGAT3 is over-expressed in tumor, although a few such as KICH and CHOL show the opposite, repressed pattern.

KIRC, KICH, and CHOL are the cancer types where MOGAT3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MOGAT3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	+1.599	<.001	10	view →
KICH	Male	II,III,IV	−1.130	<.001	8	view →
CHOL	Female	All	−3.003	<.001	5	view →
STAD	Female	All	+2.154	.009	4	view →
BLCA	Female	IV	+0.053	.011	4	view →
COAD	Female	All	−0.695	.008	3	view →
LIHC	Male	All	+0.933	.004	2	view →
BRCA	Female	All	−0.017	.007	2	view →
ESCA	All	All	+2.342	.021	1	view →
HNSC	All	All	+0.043	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

MOGAT3–KIRC

Open the KIRC breakdown →